ATE460406T1 - Bicyclische verbindung, deren herstellung und verwendung - Google Patents

Bicyclische verbindung, deren herstellung und verwendung

Info

Publication number
ATE460406T1
ATE460406T1 AT02762751T AT02762751T ATE460406T1 AT E460406 T1 ATE460406 T1 AT E460406T1 AT 02762751 T AT02762751 T AT 02762751T AT 02762751 T AT02762751 T AT 02762751T AT E460406 T1 ATE460406 T1 AT E460406T1
Authority
AT
Austria
Prior art keywords
production
bicyclic compound
bicyclic
compound
Prior art date
Application number
AT02762751T
Other languages
English (en)
Inventor
Mitsuru Shiraishi
Masanori Baba
Katsuji Aikawa
Naoyuki Kanzaki
Masaki Seto
Yuji Iizawa
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Application granted granted Critical
Publication of ATE460406T1 publication Critical patent/ATE460406T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/16—Eight-membered rings
    • C07D313/20—Eight-membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
AT02762751T 2001-08-08 2002-08-07 Bicyclische verbindung, deren herstellung und verwendung ATE460406T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001240750 2001-08-08
JP2002066809 2002-03-12
PCT/JP2002/008043 WO2003014105A1 (en) 2001-08-08 2002-08-07 Bicyclic compound, production and use as hiv inhibitors

Publications (1)

Publication Number Publication Date
ATE460406T1 true ATE460406T1 (de) 2010-03-15

Family

ID=26620186

Family Applications (2)

Application Number Title Priority Date Filing Date
AT10150963T ATE539062T1 (de) 2001-08-08 2002-08-07 Bizyklishe verbindung, ihre herstellung und verwendung
AT02762751T ATE460406T1 (de) 2001-08-08 2002-08-07 Bicyclische verbindung, deren herstellung und verwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT10150963T ATE539062T1 (de) 2001-08-08 2002-08-07 Bizyklishe verbindung, ihre herstellung und verwendung

Country Status (14)

Country Link
US (7) US7371772B2 (de)
EP (3) EP1423376B1 (de)
JP (4) JP4316203B2 (de)
AR (1) AR034985A1 (de)
AT (2) ATE539062T1 (de)
AU (1) AU2002328092A1 (de)
CA (2) CA2607992A1 (de)
DE (1) DE60235632D1 (de)
DK (2) DK1423376T3 (de)
ES (2) ES2376855T3 (de)
HK (1) HK1142886A1 (de)
PE (1) PE20030329A1 (de)
PT (2) PT2206702E (de)
WO (1) WO2003014105A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1423376T3 (da) 2001-08-08 2010-06-28 Tobira Therapeutics Inc Bicyklisk forbindelse, fremstilling og anvendelse deraf
WO2003076411A1 (fr) * 2002-03-12 2003-09-18 Takeda Pharmaceutical Company Limited Procede de production d'un derive sulfoxyde actif sur le plan optique
US20060160864A1 (en) * 2003-02-07 2006-07-20 Mitsuru Shiraishi Acrylamide derivative, process for producing the same, and use
US20060178359A1 (en) * 2003-02-07 2006-08-10 Mitsuru Shiraishi Tricyclic compound, process for producing the same, and use
US7288654B2 (en) 2003-02-07 2007-10-30 Takeda Pharmaceutical Company Ltd Fused-ring pyridine derivative, process for producing the same, and use
EP1728504B1 (de) * 2004-03-24 2013-07-31 Takeda Pharmaceutical Company Limited Emulsionsstabilisator
JPWO2005089716A1 (ja) * 2004-03-24 2008-01-31 武田薬品工業株式会社 高含量化製剤
US20050260139A1 (en) * 2004-03-30 2005-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on anticholinergics and CCR2 receptor antagonists
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
US20080031942A1 (en) * 2004-12-03 2008-02-07 Takeda Pharmaceutical Company Limited Solid Preparation
US8426387B2 (en) * 2006-03-31 2013-04-23 Stephen Carper Treatments for cancer
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
WO2008109591A1 (en) * 2007-03-08 2008-09-12 Lexicon Pharmaceuticals, Inc. Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
AU2009305619B2 (en) * 2008-10-17 2012-06-21 Invasc Therapeutics, Inc. Compositions and methods for treatment of renin-angiotensin aldosterone system (RAAS)-related disorders
EA201890254A3 (ru) 2009-11-27 2019-02-28 Джензим Корпорэйшн Ингибиторы глюкозилцерамидсинтазы
BR112012024522A2 (pt) 2010-04-02 2017-08-08 Phivco 1 Llc combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio
WO2012047630A2 (en) * 2010-09-27 2012-04-12 Martin Teintze N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
EP3119401A4 (de) * 2014-03-21 2017-12-13 Tobira Therapeutics, Inc. Cenicriviroc zur behandlung von fibrose
MA39991A (fr) * 2014-06-02 2015-12-10 Tobira Therapeutics Inc Cénicriviroc pour le traitement de l'infection à vih-2
JP2017526713A (ja) 2014-09-12 2017-09-14 トビラ セラピューティクス， インコーポレイテッド 線維症を処置するためのセニクリビロック併用療法
MX2017008280A (es) 2014-12-23 2017-12-07 Tobira Therapeutics Inc Proceso para elaborar cenicriviroc y analogos relacionados.
CN107405403B (zh) 2015-02-10 2021-04-20 妥必徕疗治公司 用于治疗纤维化和腹膜炎的塞尼克韦罗
KR101938036B1 (ko) * 2015-04-16 2019-01-14 서울대학교산학협력단 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법
WO2017223155A1 (en) 2016-06-21 2017-12-28 Tobira Therapeutics, Inc. Purified cenicriviroc and purified intermediates for making cenicriviroc
BR112019003987A2 (pt) * 2016-08-31 2019-05-28 Tobira Therapeutics Inc formas sólidas de mesilato de cenicriviroc e processos de produção das formas sólidas de mesilato de cenicriviroc
WO2018103757A1 (zh) 2016-12-09 2018-06-14 广东众生药业股份有限公司 作为ccr2/ccr5受体拮抗剂的联苯化合物
EP3585384A1 (de) 2017-02-24 2020-01-01 Genfit Pharmazeutische zusammensetzungen für eine kombinationstherapie
CN111630047B (zh) * 2018-02-02 2023-05-23 四川科伦博泰生物医药股份有限公司 含有羧酸基团的苯并氮杂环类化合物及其制备方法和用途
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
WO2019238041A1 (zh) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 一种丙烯酰胺类化合物的晶型及其制备方法
WO2020207263A1 (zh) * 2019-04-08 2020-10-15 四川科伦博泰生物医药股份有限公司 苯并咪唑化合物、其制备方法及其用途
JP7292588B2 (ja) * 2019-06-24 2023-06-19 无錫▲りん▼方生物医薬科技有限公司 Ｃｃｒ２／ｃｃｒ５アンタゴニストとしてのヘテロシクロアルキル系化合物
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
US20230183221A1 (en) 2020-05-22 2023-06-15 Medshine Discovery Inc. Pyridine derivative and application thereof
CN112472678A (zh) * 2020-11-12 2021-03-12 澳美制药厂有限公司 肾素那敏制剂及其制备方法
WO2023143112A1 (zh) * 2022-01-26 2023-08-03 无锡瓴方生物医药科技有限公司 氮杂苯并八元环化合物的盐型、晶型及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
EP0769015B1 (de) 1994-07-04 2001-03-14 Takeda Chemical Industries, Ltd. Phosphonsäure verbindungen imre herstellung und verwendung
RU2167649C2 (ru) 1995-08-11 2001-05-27 Ниссан Кемикал Индастриз, Лтд. Способ получения твердой дисперсии умеренно водорастворимого лекарственного вещества (варианты) и фармацевтическая композиция
CN1152686C (zh) 1997-10-20 2004-06-09 大日本制药株式会社 稳定化药用组合物
CA2304959A1 (en) * 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
AU5301599A (en) * 1998-08-20 2000-03-14 Takeda Chemical Industries Ltd. Quaternary ammonium salts and their use
CA2244097A1 (en) 1998-08-21 2000-02-21 Bernard Charles Sherman Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid
CA2353635A1 (en) 1998-12-21 2000-06-29 Takeda Chemical Industries, Ltd. Anilide derivative, production and use thereof
EP1172097B1 (de) 1999-04-12 2004-09-08 Shionogi & Co., Ltd. Verfahren zur herstellung von arzneimitteln eines basischen hydrophoben wirkstoffs
JP2001026586A (ja) 1999-05-07 2001-01-30 Takeda Chem Ind Ltd 環状化合物およびその用途
EP1211239A4 (de) 1999-09-06 2003-08-06 Takeda Chemical Industries Ltd Verfahren zur herstellung von 2,3-dihydroazepin-derivaten
DK1423376T3 (da) * 2001-08-08 2010-06-28 Tobira Therapeutics Inc Bicyklisk forbindelse, fremstilling og anvendelse deraf
WO2003076411A1 (fr) 2002-03-12 2003-09-18 Takeda Pharmaceutical Company Limited Procede de production d'un derive sulfoxyde actif sur le plan optique
JPWO2005089716A1 (ja) * 2004-03-24 2008-01-31 武田薬品工業株式会社 高含量化製剤
EP1728504B1 (de) * 2004-03-24 2013-07-31 Takeda Pharmaceutical Company Limited Emulsionsstabilisator
US20080031942A1 (en) * 2004-12-03 2008-02-07 Takeda Pharmaceutical Company Limited Solid Preparation
WO2008030853A2 (en) 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
BR112012024522A2 (pt) 2010-04-02 2017-08-08 Phivco 1 Llc combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio
US9562038B2 (en) 2010-11-18 2017-02-07 Yale University Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
EP2723360B1 (de) 2011-06-27 2017-05-31 Université Pierre et Marie Curie (Paris 6) Ccr2-antagonistenpeptide
MY180145A (en) 2013-05-15 2020-11-23 Tobira Therapeutics Inc Cenicriviroc compositions and methods of making and using the same
EP3119401A4 (de) 2014-03-21 2017-12-13 Tobira Therapeutics, Inc. Cenicriviroc zur behandlung von fibrose
MX2017008280A (es) 2014-12-23 2017-12-07 Tobira Therapeutics Inc Proceso para elaborar cenicriviroc y analogos relacionados.
CN107405403B (zh) 2015-02-10 2021-04-20 妥必徕疗治公司 用于治疗纤维化和腹膜炎的塞尼克韦罗

Also Published As

Publication number Publication date
US20080161287A1 (en) 2008-07-03
EP1889839B1 (de) 2013-11-06
PE20030329A1 (es) 2003-05-12
ES2376855T3 (es) 2012-03-20
US20090030032A1 (en) 2009-01-29
US20040259876A1 (en) 2004-12-23
US8362058B2 (en) 2013-01-29
PT2206702E (pt) 2012-02-03
CA2607992A1 (en) 2003-02-20
CA2459172A1 (en) 2003-02-20
EP2206702B1 (de) 2011-12-28
JP4358851B2 (ja) 2009-11-04
EP2206702A1 (de) 2010-07-14
WO2003014105A9 (en) 2003-11-20
EP1423376B1 (de) 2010-03-10
EP1889839A1 (de) 2008-02-20
EP1423376A1 (de) 2004-06-02
JP2013136629A (ja) 2013-07-11
US8183273B2 (en) 2012-05-22
CA2459172C (en) 2011-07-05
PT1423376E (pt) 2010-04-12
US20190038604A1 (en) 2019-02-07
ATE539062T1 (de) 2012-01-15
US10045968B2 (en) 2018-08-14
JP5275148B2 (ja) 2013-08-28
WO2003014105A1 (en) 2003-02-20
DE60235632D1 (de) 2010-04-22
DK2206702T3 (da) 2012-02-13
DK1423376T3 (da) 2010-06-28
US20160008326A1 (en) 2016-01-14
AR034985A1 (es) 2004-03-24
JP2007084578A (ja) 2007-04-05
HK1142886A1 (en) 2010-12-17
US8741943B2 (en) 2014-06-03
AU2002328092A1 (en) 2003-02-24
US20200297700A1 (en) 2020-09-24
JP2003335776A (ja) 2003-11-28
JP4316203B2 (ja) 2009-08-19
ES2339340T3 (es) 2010-05-19
US20120232028A1 (en) 2012-09-13
US7371772B2 (en) 2008-05-13
JP2009209154A (ja) 2009-09-17

Similar Documents

Publication Publication Date Title
ATE460406T1 (de) Bicyclische verbindung, deren herstellung und verwendung
EG25011A (en) Amino-piperidin-1-yl-xanthines, the production thereof and the use of the same as medicaments.
DE60235547D1 (de) En daraus, deren herstellung und verwendung
ATE319684T1 (de) Sulfonamidderivate, deren herstellung und deren verwendung als medikamente
ATE294171T1 (de) Phenylsulfonyl-1,3-dihydro-2h-indol-2-on derivate,deren herstellung und deren therapeutische verwendung
DE60225385D1 (de) Autentisches Document und dessen Herstellungsverfahren
DE60232986D1 (de) Thermoplastharzzusammensetzung, formkörper und herstellungsverfahren dafür
ATE293644T1 (de) Polyolefin und die herstellung davon
ATE424202T1 (de) Substituierte 2-thio-3,5-dicyano-4-phenyl-6- aminopyridine und ihre verwendung
HUP0401293A3 (en) Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
DE60238358D1 (de) Naturkautschuk-masterbatch dessen Herstellungsverfahren, und Naturkautschukzusammensetzung
AU2003293757A1 (en) Novel substituted imidazo-pyridinones and imidazo-pyridazeiones, the production and use thereof as medicaments
ATE308557T1 (de) Antipicornavirale verbindungen, deren herstellung und verwendung
ATE302604T1 (de) Thienylazolylalkoxyethanamine, deren herstellung und deren verwendung als medikamente
DE60200427D1 (de) Vernetzbare Fluorelastomerzusammensetzungen, ihre Herstellung und Verwendung
DE50208287D1 (de) Bicyclische n-arylamide
DE60216345D1 (de) Gummimischung und deren Verwendung
DE60200719D1 (de) Filmbildende Zusammensetzung, poröser Film und deren Herstellung
ATE326467T1 (de) Imidazo 1,2-aöpyridine
ATE265454T1 (de) Phenyloxazol-1,4-diazabicyclo(3.2.2)nonanderiva e,ihre herstellung und ihre therapeutische verwendung
ATE312828T1 (de) Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung
DE50214244D1 (de) Klauenpolläufer und dessen herstellverfahren
ATE251170T1 (de) Titanverbindungen, deren herstellung und verwendung
DE60334632D1 (de) Mechanolumineszenzstoff und dessen herstellung
MXPA03006648A (es) Compuestos antitombroticos, su preparacion y su utilizacion como medicamentos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1423376

Country of ref document: EP